Overview

A Study to Evaluate the PK, Safety and Tolerability of GMI-1271 With and Without Filgrastim in Healthy Adult Subjects

Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
Phase 1, open-label, parallel, active-controlled, multiple IV dose, proof of concept study conducted at one study center in the United States (US).
Phase:
Phase 1
Details
Lead Sponsor:
GlycoMimetics Incorporated
Collaborator:
Celerion
Treatments:
Lenograstim